Pediatrix Medical Group, Inc. (MD): Results of Operations and Financial Condition
Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations using the reported Q2 revenue, Adjusted EPS, Adjusted EBITDA, and the reaffirmed full-year Adjusted EBITDA range. The filing also highlights drivers (reimbursement mix, collections, payor mix) and offsets (same-unit volume decline) plus cash flow and leverage context.
Market read
A fresh earnings release with specific quarterly numbers and a reaffirmed full-year EBITDA range provides actionable inputs for valuation and positioning.
What to watch
Cash from continuing operations fell year over year ($126.3M vs $138.1M), and cash balances declined materially from Dec 31, 2025 ($375.2M to $288.9M), which may temper enthusiasm even with EBITDA guidance reaffirmed.
Pediatrix Medical Group Reports Second Quarter Results
Second-quarter revenue, Adjusted EBITDA, net income and Adjusted EPS increased from the prior-year period, supported by recent acquisitions and reimbursement-related same-unit gains. Patient volumes declined, expenses rose faster than same-unit revenue, and the company reaffirmed rather than raised its full-year Adjusted EBITDA outlook.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenue, three months ended June 30, 2026GAAP | $487.8 million | – | 4.0% |
| Same-unit revenue growth, three months ended June 30, 2026other | 1.9 percent | – | – |
| Non-same unit activity growth, three months ended June 30, 2026other | 2.1 percent | – | – |
| Practice salaries and benefits expense, 2026 second quarterGAAP | $336.1 million | – | – |
| General and administrative expenses, 2026 second quarterGAAP | $61.3 million | – | – |
| Transformational and restructuring related expenses, 2026 second quarterGAAP | $8.5 million | – | – |
| Adjusted EBITDA, 2026 second quarternon-GAAP | $76.4 million | – | – |
| Depreciation and amortization expense, second quarter of 2026GAAP | $5.8 million | – | – |
| Interest expense, second quarter of 2026GAAP | $8.2 million | – | – |
| Investment and other income, second quarter of 2026GAAP | $4.5 million | – | – |
| Net income, 2026 second quarterGAAP | $39.8 million | – | – |
| Diluted earnings per share, 2026 second quarterGAAP | $0.49 per diluted share | – | – |
| Weighted average shares outstanding, 2026 second quarterGAAP | 81.4 million | – | – |
| Adjusted EPS, second quarter of 2026non-GAAP | $0.63 | – | – |
| Revenue, six months ended June 30, 2026GAAP | $964.0 million | – | – |
| Net income, six months ended June 30, 2026GAAP | $69.4 million | – | – |
| Earnings per share, six months ended June 30, 2026GAAP | $0.85 per share | – | – |
| Weighted average shares outstanding, six months ended June 30, 2026GAAP | 82.0 million shares outstanding | – | – |
| Adjusted EBITDA, six months ended June 30, 2026non-GAAP | $134.6 million | – | – |
| Adjusted EPS, six months ended June 30, 2026non-GAAP | $1.07 | – | – |
| Cash from continuing operations, second quarter of 2026GAAP | $126.3 million | – | – |
full year 2026 outlook
- NoteAdjusted EBITDA: $280 million to $300 million
Capital returns
- Used $42.7 million to fund share repurchases during the second quarter of 2026.
What drove it
- Recent acquisitions drove growth in non-same unit activity, partially offset by practice dispositions.
- Same-unit revenue from net reimbursement-related factors increased by 4.0 percent, reflecting improved cash collections, a favorable shift in payor mix and higher patient acuity, primarily in neonatology.
- The percentage of services reimbursed by commercial and other non-government payors increased by 135 basis points compared to the prior-year period.
- Adjusted EBITDA increased primarily due to net favorable impacts from recent acquisitions.
- Interest expense reflected modestly lower interest rates and borrowings.
Concerns
- Same-unit revenue attributable to patient volume decreased by 2.1 percent for the 2026 second quarter compared to the prior-year period.
- Hospital-based patient services decreased by (2.8)% and office-based patient services decreased by (1.2)% for the three months ended June 30, 2026.
- NICU days decreased by (3.2)% for the three months ended June 30, 2026.
- The decrease in same-unit results was due to higher expenses as compared to revenue growth.
- Practice salaries and benefits expense, general and administrative expenses, and transformational and restructuring related expenses increased from the prior-year period.
What to watch
- Whether reimbursement-related factors, including cash collections, payor mix and patient acuity, continue to offset patient-volume declines.
- Performance of recent acquisitions and the effects of practice dispositions on non-same unit activity.
- Clinical salaries, malpractice expense, executive transition related costs, cash collection expense and revenue cycle management transition activities.
- Delivery against the reaffirmed full-year 2026 Adjusted EBITDA range of $280 million to $300 million.
- Further share repurchases, capital expenditures, cash from continuing operations and borrowings under the revolving line of credit.
Balance sheet and cash flow
- Cash and cash equivalents of $288.9 million at June 30, 2026, compared to $375.2 million at December 31, 2025.
- Net accounts receivable of $227.6 million at June 30, 2026.
- Cash from continuing operations of $126.3 million for the second quarter of 2026, compared to $138.1 million during the second quarter of 2025.
- Used $1.4 million to fund capital expenditures during the second quarter of 2026.
- Total debt outstanding of $584 million at June 30, 2026, consisting of $400 million in 5.375% Senior Notes due 2030 and $184 million in borrowings under its Term A Loan.
- No outstanding borrowings under its $450 million revolving line of credit at June 30, 2026.
Analysis
Pediatrix reported second-quarter net revenue of $487.8 million, compared with $468.8 million for the prior-year period. The company attributed the $19.0 million, or 4.0%, increase to 2.1 percent growth in non-same unit activity, driven by recent acquisitions and partly offset by practice dispositions, and 1.9 percent growth in same-unit revenue. For the six months ended June 30, 2026, revenue was $964.0 million, compared with $927.2 million for the prior-year period.
The mix of same-unit performance was favorable on reimbursement but negative on utilization. Same-unit revenue from net reimbursement-related factors increased by 4.0 percent, driven by improved cash collections, a favorable payor-mix shift and higher patient acuity, primarily in neonatology. The percentage of services reimbursed by commercial and other non-government payors increased by 135 basis points. In contrast, same-unit revenue attributable to patient volume decreased by 2.1 percent, with hospital-based patient services down (2.8)%, office-based patient services down (1.2)% and NICU days down (3.2)% for the three-month period.
Profitability improved in dollar terms, although the release identifies expense growth as a constraint on same-unit results. Adjusted EBITDA was $76.4 million, compared with $73.2 million, principally due to net favorable impacts from recent acquisitions, partly offset by higher expenses relative to same-unit revenue growth. Practice salaries and benefits expense was $336.1 million, general and administrative expenses were $61.3 million, and transformational and restructuring related expenses were $8.5 million. Net income was $39.8 million, or $0.49 per diluted share, compared with $39.3 million, or $0.46 per diluted share. Adjusted EPS was $0.63, compared with $0.53.
Cash and capital allocation warrant attention. Cash and cash equivalents were $288.9 million at June 30, 2026, compared with $375.2 million at December 31, 2025. The company generated $126.3 million of cash from continuing operations in the quarter, compared with $138.1 million during the second quarter of 2025, and used $42.7 million for share repurchases and $1.4 million for capital expenditures. Total debt outstanding was $584 million, while the $450 million revolving line of credit had no outstanding borrowings.
Pediatrix reaffirmed full-year 2026 Adjusted EBITDA guidance of $280 million to $300 million. No revenue, gross-margin, operating-expense or tax-rate outlook was provided. The principal operating variables identified in the release are the continuation of reimbursement and payor-mix benefits, the pace of patient-volume trends, expense management, and the contribution from recent acquisitions and practice portfolio actions.
Management, verbatim
Our strong results this quarter were in line with our expectations and reflect continued favorable trends in the performance of recent acquisitions and same-unit reimbursement metrics.
Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group
With a coveted, strong balance sheet, we believe we have exceptional financial flexibility to fund organic growth initiatives while remaining well-positioned to pursue potential high-value strategic opportunities.
Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group
Not in the filing
stated, not guessed- Gross profit and gross margin were not reported.
- GAAP operating income was not reported.
- Income tax expense and tax rate were not reported.
- Free cash flow was not reported.
- Quarter-over-quarter comparisons were not reported for the disclosed key metrics.
- Revenue, gross-margin, operating-expense and tax-rate guidance were not provided.
- Segment revenue was not reported.
- Dividends were not reported.
- Prior outlook was not provided, so comparison of actual results with prior guidance is unavailable.
- A CFO commentary document was not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Pediatrix Medical Group’s SEC Form 8-K (Item 2.02) with Q2 2026 operating results and financial condition, including a reaffirmed full-year 2026 Adjusted EBITDA outlook.
Ticker impact
Pediatrix reported Q2 2026 results, including Adjusted EPS of $0.63 and reaffirmed full-year 2026 Adjusted EBITDA guidance of $280M to $300M.
Near-term bias upward if investors view same-unit reimbursement and acquisition integration as durable; watch cash flow and same-unit volume softness.
The filing provides concrete quarterly datapoints (revenue, net income, Adjusted EPS, Adjusted EBITDA) plus a specific reaffirmed full-year EBITDA range, which are direct inputs to valuation and forward expectations.
Market effects
Reinforces that physician services operators can grow via acquisitions and reimbursement mix, potentially supporting sector sentiment around managed-care contracting and collections.
No explicit regional impact beyond company-specific performance.
Primarily US healthcare services; limited direct global read-through from the filing.
Counterpoint
Despite improved reimbursement metrics, same-unit patient volume declined (down 2.1%), which could pressure future growth if volume weakness persists.
Key entities
- issuerPediatrix Medical Group, Inc.
Reports Q2 2026 results, cash flow, debt levels, and reaffirms full-year 2026 Adjusted EBITDA guidance.
- executiveMark S. Ordan
CEO quoted attributing results to acquisition performance and same-unit reimbursement metrics.
- executiveKasandra H. Rossi
CFO and Treasurer listed as contact for the release.
